Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice - PubMed (original) (raw)
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice
Daniel A Adams et al. Antimicrob Agents Chemother. 2007 Aug.
Abstract
Several recent outbreaks of Clostridium difficile-associated disease (CDAD) have been attributed to the emergence of an epidemic strain with increased resistance to fluoroquinolone antibiotics. Some clinical studies have suggested that fluoroquinolones with enhanced antianaerobic activity (i.e., gatifloxacin and moxifloxacin) may have a greater propensity to induce CDAD than ciprofloxacin and levofloxacin do. We examined the effects of subcutaneous fluoroquinolone treatment on in vitro growth of and toxin production by epidemic and nonepidemic C. difficile isolates in cecal contents of mice and evaluated the potential for these agents to inhibit fluoroquinolone-susceptible isolates during treatment. When C. difficile isolates were inoculated into cecal contents collected 2 days after the final antibiotic dose, gatifloxacin and moxifloxacin promoted significantly more growth and toxin production than ciprofloxacin and levofloxacin did. During treatment, gatifloxacin and moxifloxacin inhibited growth of fluoroquinolone-susceptible but not fluoroquinolone-resistant isolates. Ciprofloxacin and levofloxacin promoted growth of C. difficile when administered at higher doses (i.e., 20 times the human dose in mg/kg of body weight), and levofloxacin inhibited growth of fluoroquinolone-susceptible, but not fluoroquinolone-resistant, C. difficile isolates when administered in combination with ceftriaxone. Thus, fluoroquinolones with enhanced antianaerobic activity (i.e., gatifloxacin and moxifloxacin) promoted C. difficile growth to a greater extent than did ciprofloxacin and levofloxacin in this model. However, our findings suggest that fluoroquinolones may exert selective pressure favoring the emergence of epidemic fluoroquinolone-resistant C. difficile strains by inhibiting fluoroquinolone-susceptible but not fluoroquinolone-resistant isolates during treatment and that agents such as levofloxacin or ciprofloxacin can exert such selective pressure when administered in combination with antibiotics that disrupt the anaerobic microflora.
Figures
FIG. 1.
Effect of antibiotic treatment on growth of (A) and toxin production by (B) Clostridium difficile in the cecal contents of mice. Strains 3 and 4 were epidemic BI strains. Mice received daily subcutaneous antibiotic treatment for 5 days. Two days after the final antibiotic dose, cecal contents were collected and inoculated with 104 CFU/ml of the C. difficile test strains. Samples were incubated anaerobically for 48 h, and then serial dilutions were plated onto selective medium for quantification of C. difficile and assayed for toxin production. Mean toxin titers are expressed as the reciprocal of the highest serial 10-fold dilution that gave positive results. For ciprofloxacin and levofloxacin, 12× and 20× refer to 12 and 20 times the initial dosage, respectively. Error bars represent standard errors.
FIG. 2.
Effect of antibiotic treatment on growth of Clostridium difficile in the cecal contents of mice during treatment. Mice received daily subcutaneous antibiotic treatment for 5 days. Two hours after the final antibiotic dose, cecal contents were collected and inoculated with 104 CFU/ml of the C. difficile test strains. Samples were incubated anaerobically for 48 h, and then serial dilutions were plated onto selective medium for quantification of C. difficile. Error bars represent standard errors. FQ, fluoroquinolone.
FIG. 3.
Effect of clindamycin treatment on growth of clindamycin-resistant (strain 4) and clindamycin-susceptible (strains 5 and 6) Clostridium difficile strains in the cecal contents of mice during or after treatment. Mice received daily subcutaneous clindamycin treatment for 5 days. Two hours (during treatment) or 2 days (after treatment) after the final antibiotic dose, cecal contents were collected and inoculated with 104 CFU/ml of the C. difficile test strains. Samples were incubated anaerobically for 48 h, and then serial dilutions were plated onto selective medium for quantification of C. difficile. Error bars represent standard errors.
Similar articles
- Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.
Pultz NJ, Donskey CJ. Pultz NJ, et al. Antimicrob Agents Chemother. 2005 Aug;49(8):3529-32. doi: 10.1128/AAC.49.8.3529-3532.2005. Antimicrob Agents Chemother. 2005. PMID: 16048976 Free PMC article. - Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. Drudy D, et al. Infect Control Hosp Epidemiol. 2007 Aug;28(8):932-40. doi: 10.1086/519181. Epub 2007 Jun 29. Infect Control Hosp Epidemiol. 2007. PMID: 17620240 - High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S. Drudy D, et al. J Antimicrob Chemother. 2006 Dec;58(6):1264-7. doi: 10.1093/jac/dkl398. Epub 2006 Oct 3. J Antimicrob Chemother. 2006. PMID: 17018563 - Antimicrobial-associated risk factors for Clostridium difficile infection.
Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Owens RC Jr, et al. Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S19-31. doi: 10.1086/521859. Clin Infect Dis. 2008. PMID: 18177218 Review. - Update on Clostridium difficile associated disease.
Cloud J, Kelly CP. Cloud J, et al. Curr Opin Gastroenterol. 2007 Jan;23(1):4-9. doi: 10.1097/MOG.0b013e32801184ac. Curr Opin Gastroenterol. 2007. PMID: 17133077 Review.
Cited by
- Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures.
Wieczorkiewicz JT, Skinner AM, Cheknis A, Petrella LA, Stevens VW, Wright LM, Gerding DN, Johnson S. Wieczorkiewicz JT, et al. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0069824. doi: 10.1128/aac.00698-24. Epub 2024 Jul 2. Antimicrob Agents Chemother. 2024. PMID: 38953622 - Why Does Doxycycline Pose a Relatively Low Risk for Promotion of Clostridioides difficile Infection?
Xu D, Mana TSC, Cadnum JL, Deshpande A, Afsari F, Sangwan N, Donskey CJ. Xu D, et al. Pathog Immun. 2022 Jun 21;7(1):81-94. doi: 10.20411/pai.v7i1.512. eCollection 2022. Pathog Immun. 2022. PMID: 35800258 Free PMC article. - Effect of sub-MIC values of metronidazole, ciprofloxacin, and imipenem on the growth and toxin production in Clostridioides difficile.
Shayegan Mehr FS, Azimirad M, Mansouri Gilani SN, Ghafurian A, Yadegar A. Shayegan Mehr FS, et al. Gastroenterol Hepatol Bed Bench. 2019;12(Suppl1):S163-S168. Gastroenterol Hepatol Bed Bench. 2019. PMID: 32099618 Free PMC article. - Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital.
Sheth PM, Douchant K, Uyanwune Y, Larocque M, Anantharajah A, Borgundvaag E, Dales L, McCreight L, McNaught L, Moore C, Ragan K, McGeer A, Broukhanski G. Sheth PM, et al. PLoS One. 2019 Feb 11;14(2):e0207138. doi: 10.1371/journal.pone.0207138. eCollection 2019. PLoS One. 2019. PMID: 30742636 Free PMC article. - The Intersection Between Colonization Resistance, Antimicrobial Stewardship, and Clostridium difficile.
Rosa R, Donskey CJ, Munoz-Price LS. Rosa R, et al. Curr Infect Dis Rep. 2018 Jun 7;20(8):27. doi: 10.1007/s11908-018-0631-z. Curr Infect Dis Rep. 2018. PMID: 29882079 Review.
References
- Borriello, S. P., F. E. Barclay, and A. R. Welch. 1988. Evaluation of the predictive capability of an in-vitro model of colonization resistance to Clostridium difficile infection. Microb. Ecol. Health Dis. 1:61-64.
- Gaynes, R., D. Rimland, E. Killum, K. Lowery, T. M. Johnson, G. Killgore, and F. C. Tenover. 2004. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin. Infect. Dis. 38:640-645. - PubMed
- Gerding, D. N. 2004. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin. Infect. Dis. 38:646-648. - PubMed
- Golledge, C. L., C. F. Carson, G. L. O'Neill, R. A. Bowman, and T. V. Riley. 1992. Ciprofloxacin and Clostridium difficile-associated diarrhea. J. Antimicrob. Chemother. 30:141-147. - PubMed
- Johnson, S., M. H. Samore, K. A. Farrow, G. E. Killgore, F. C. Tenover, D. Lyras, J. I. Rood, P. DeGirolami, A. L. Baltch, M. E. Rafferty, S. M. Pear, and D. N. Gerding. 1999. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341:1645-1651. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical